Kah Jing Lim, PhD

A Ph.D. graduate in Pathobiology from the Johns Hopkins University School of Medicine, Dr. Kah Jing Lim is a highly detail-oriented, efficient and adaptable research scientist. Her expertise is in molecular biology, cancer biology, the Natural Health Products industry, GMP manufacturing, and regulatory compliance. 

She has over 10 years of industry experience across different departments in a natural health product R&D and GMP manufacturing facility. Dr. Lim played a significant role in revamping and streamlining the Quality Management System and Batch Documentation Process at the company. 

As Research & Innovation Manager, Dr. Lim also led the Advanced Development Laboratory team for Natural Health Product research. She spearheaded the development of products targeting heart, respiratory, joint pain and energy levels. Notably, she developed an antioxidant formulation and designed experiments to measure pre-clinical effects in promotion of tissue regeneration, protection against UV-mediated oxidative stress, infection-induced inflammation and vascular development during tumor-induced angiogenesis. This new formula boosted the client's overall sales by 30%. In addition to setting up the Research Laboratory, Dr. Lim also played key roles in building the Microbiology and Analytical laboratories. 

Dr. Lim currently works in a Scientific Advisory role, advising and supporting the Quality, Compliance & Regulatory Affairs Teams. Dr. Lim is highly competent in preparing and reviewing SOPs, Policies, Forms and other documentation for the GMP environment, interpreting regulatory requirements (Health Canada, FDA, USP) and auditing. She is also adept at implementing and using Business and Quality Management software programmes and other automation tools to increase efficiency in the workplace. 

Dr. Lim aspires to make a difference to people’s health by contributing her scientific technical knowledge and a wide skills set in Quality, Research, Operations and IT.

Honours and Awards

  • Mitacs Enterprise Graduate Internship, 2013
  • Margaret Lee Fellowship, Johns Hopkins University, Maryland, USA, 2007-2012
  • Dean’s List, Faculty of Science, National University of Singapore, Singapore, Academic Year 2002/2003 Semester 2 & 2003/2004 Semester 1

  • 2007-2013 Ph.D. Pathobiology Graduate Program, School of Medicine, Johns Hopkins University, Maryland, USA
  • 2002-2006 B.Sc. Life Science, Biomedical Science (2nd Upper Honours); Minor in Computational Science, National University of Singapore, Singapore


Peer Reviewed Research Papers 
  • Jakhar R, Luijten MNH, Wong AXF, Cheng B, Guo K, Neo SP, Au B, Kulkarni M, Lim KJ, Maimaiti J, Chong HC, Lim EH, Tan TBK, Ong KW, Sim Y, Wong JSL, Khoo JBK, Ho JTS, Chua BT, Sinha I, Wang X, Connolly JE, Gunaratne J, Crasta KC. Autophagy Governs Protumorigenic Effects of Mitotic Slippage-induced Senescence. Mol Cancer Res. 2018 Nov;16(11):1625-1640.
  • He Q, Au B, Kulkarni M, Shen Y, Lim KJ, Maimaiti J, Wong CK, Luijten MNH, Chong HC, Lim EH, Rancati G, Sinha I, Fu Z, Wang X, Connolly JE, Crasta KC.Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects. Oncogenesis. 2018 Aug 15;7(8):62.
    Lim KJ, Brandt WD, Heth JA, Muraszko KM, Fan X, Bar EE, Eberhart CG. Lateral inhibition of Notch signaling in neoplastic cells. Oncotarget. 2015 Jan 30;6(3):1666-77.
  • Asnaghi L, Lin MH, Lim KS, Lim KJ, Tripathy A, Wendeborn M, Merbs SL, HandaJT, Sodhi A, Bar EE, Eberhart CG. Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation. PLoS One. 2014 Aug 28;9(8):e105372.
  • Lim KS, Lim KJ, Price AC, Orr BA, Eberhart CG, Bar EE. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene. 2014 Aug28;33(35):4433-41.
  • Lim KJ, Rajan K, Eberhart CG. Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and Notch signaling. Anticancer Res. 2012 Jul;32(7):2689-96.
  • Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther. 2011 Mar 1;11(5):464-73.

White Paper
  • Li, F., Maimaiti, J., McConnell, C., Tubman, J., Porter, L., Sinha, I. and Lim K.J. (2018). Design and development of an antioxidant formulation with measurable effects against oxidative stress, infection induced inflammation, and vascular development during tumour induced angiogenesis

Conference Presentations 
  • Nov 2012, Society for Neuro-Oncology Annual Meeting, Chicago, USA - Oral Presentation, “Notch Ligands, Lateral Inhibition and Stem-like Glioblastoma Cells”
  • Nov 2011, Society for Neuro-Oncology Annual Meeting, Chicago, USA - Poster Presentation, “The Role of Lateral Inhibition in the Maintenance of Cancer Stem Cells”
  • Feb 2011, American Association for Cancer Research, Stem Cells, Development and CancerMeeting, Vancouver BC, Canada - Poster Presentation, “Using nanocurcumin to treat medulloblastoma and glioblastoma”
  • Nov 2010, American Association for Cancer Research Annual Meeting, Washington DC, USA - Poster Presentation, “Using the natural remedies Zeng Sheng Ping and curcumin to treatmedulloblastoma and glioblastoma”
  • Oct 2009, Society for Neuro-Oncology Annual Meeting, New Orleans, USA - Poster Presentation, “Using the natural remedies Zeng Sheng Ping and curcumin to treatmedulloblastoma and glioblastoma”